PubMed Health⌕ Search

Biomedical subjects

O Bugnon

Publications and source records attributed to O Bugnon.

8 recordsLinked to original sources
PubMed2006

[Drug compliance in the elderly: determinants and support].

Drug adherence needs to be promoted in elderly patients taking multiple medications. Barriers to adherence are numerous and each barrier needs to be addressed specifically. Patients should be included in the therapeutic decision making process. Patient's life expectations and disease/treatment beliefs should be addressed. Healthcare practitioners should discuss the course of treatment with the patient proactively before any problem arises by using open-ended and informative questions. Functional and organizational barriers to adherence should be assessed throughout the treatment. A multidisciplinary approach to promote adherence is crucial and allows healthcare practitioners to combine specific skills (physician, pharmacist, nurse, etc.).

Aged↗
PubMed2000

[Evaluation of the "future non-smokers" campaign of the Swiss Society of Pharmacists].

In order to promote low threshold smoking cessation, a campaign was organized by the Swiss Society of Pharmacists in 616 Swiss pharmacies. The evaluation of this project took into consideration the actual smoking cessation counselling and the attitudes towards the campaign and tobacco prevention of the person responsible for the campaign in the pharmacy. Consultations with smokers were documented in activity statistics one week before and throughout the six weeks of the campaign. The attitude was assessed by a standardized questionnaire. 32% of the participating pharmacies completed activity statistics, 58% participated in the attitude survey. Frequency of counselling was best predicted by the customer pattern of pharmacies. The highest frequency was observed among pharmacies with a majority of non regular customers. Intensity of counselling was best predicted by the extent of preliminary training of the pharmacy personnel. The most positive view towards tobacco prevention and the highest degree of interest in a future campaign were shown by the campaign responsibilities of pharmacies characterized with both frequent and intensive counselling activity. The results of this study show that pharmacies can play a role in offering low threshold smoking cessation programs. Major pre-requisites for this are motivation with regard to prevention, as well as continuing education of pharmacists and the pharmacy personnel.

Adult↗
PubMed1995

Okadaic acid modulates exocytotic and transporter-dependent release of dopamine in bovine retina in vitro.

Bovine retinas were isolated for the study of the modulation of exocytotic and transporter-dependent release of dopamine (DA) in vitro. Endogenous DA was measured in the medium using HPLC with electrochemical detection under successive incubations with transfers in fresh medium every 30 min. As expected, potassium caused a calcium-dependent exocytotic liberation of DA. Amphetamine or tyramine induced a calcium-independent release by reversing DA transport across the plasma membrane. Okadaic acid, a specific inhibitor of phosphatases 1 and 2A, induced a slight but significant DA release in the absence of calcium. Furthermore, the toxin increased potassium-, amphetamine- or tyramine-induced DA release independently of extracellular calcium. In addition, okadaic acid completely annulled the ability of a calcium-free extracellular environment to inhibit the potassium-induced DA release. Finally, the toxin prevented the time-dependent decline in the efficacies of amphetamine or tyramine to release DA. In agreement with proposed schemes described for rat striatum, the results of the present study confirmed the existence of distinct release modes of DA in bovine retina. The results obtained with okadaic acid suggest that phosphatase 1 and/or phosphatase 2A constitute part of a direct or indirect mechanism to inhibit both exocytotic and transporter-dependent DA release.

Animals↗
PubMed1995

Effects of YM 435 and A 77636 on dopamine D-1 receptors in bovine retina in vitro.

1. Homogenates of bovine retinas were used to study the capacities of two new dopamine (DA) receptor agonists, e.g. YM 435 and A 77636, to interact with D1 receptors. 2. Adenylate cyclase experiments. YM 435 and A 77636 enhanced cAMP accumulation, with EC50 values of 1.97 microM and 22.9 nM, respectively. The receptor-mediated nature of the effects of these two novel D1 agonists was shown by the abilities of both SCH 23390 or (+)-butaclamol to inhibit the agonist-induced increase of cAMP formation. 3. Binding experiments. The same agonists were also tested for competition with 3H-SCH 23390 for binding to D1 receptors. IC50 values for YM 435 and A 77636 were 8.15 microM and 6.15 nM, respectively. 4. The results of the present report demonstrate the suitability of bovine retina in vitro to evaluate the specificity of new DA D1 agonists at the receptor level.

Adamantane↗
PubMed1994

Nitric oxide modulates endogenous dopamine release in bovine retina.

A study of the possible modulation by nitric oxide (NO) of endogenous dopamine (DA) release was performed in bovine retina in vitro. NO synthase activity was measured in retinal homogenates and totally blocked by L-nitroarginine methyl ester (L-NA). Intact retinas were also exposed to hydroxylamine, an NO-generator which significantly decreased both basal and potassium-induced liberation of DA. In contrast, dibutyryl cGMP was ineffective. Furthermore, L-NA was able to increase basal DA release, its effects being potentiated in calcium free medium. Taken together, these results suggest that endogenous NO regulates DA release via cGMP independent mechanisms.

Amino Acid Oxidoreductases↗
PubMed1993

Agonist-induced desensitization of dopamine D-1 receptors in bovine retina and rat striatum.

We have investigated agonist-induced desensitization of dopamine (DA) D-1 receptor mediated accumulation of adenosine 3':5'-cyclic monophosphate (cAMP) in bovine retinas and rat striata in vitro. Tissues were exposed to various pharmacological agents for 60 min, washed and homogenized. D-1 agonist-promoted accumulation of cAMP in the presence of adenosine 5'-triphosphate (ATP) and 5'-guanylylimidodiphosphate (GppNHp) was then measured. Retinas and striata incubated with DA or (+) SKF 38393 (100 microM each) displayed diminished capacities to accumulate cAMP when they were re-exposed to the same drugs. As expected, retinas and striata treated wtih (+) SKF 38393 also showed an attenuated formation of cAMP when restimulated with DA. In addition, D-1 receptors in retinas that had been treated with quinpirole, a D-2 agonist, did not become desensitized. Furthermore, 0.2 microM SCH 23390 prevented D-1 receptor subsensitivity caused by 100 microM DA. Interestingly, retinas and striata incubated with forskolin, a direct stimulator of adenylyl cyclase, also displayed a diminished enzymatic response to restimulation by the same agent, as well as by DA. Additionally, retinas incubated with 100 microM DA were refractory to forskolin-induced cAMP formation. Finally, results of 3H-SCH 23390 binding to control and DA-treated retinas indicated that agonist treatment did not induce significant changes in either receptor density or binding affinity. The data indicate that bovine retinas and striatal slices in vitro are suitable to investigate various aspects of the desensitization of neuronal responses to DA D-1 agonists or forskolin.

Adenylyl Cyclases↗